Amezinium metilsulfate
Chemical compound
- C01CA25 (WHO)
- In general: ℞ (Prescription only)
- 6-Methoxy-1-phenylpyridazin-1-ium-4-amine; methyl sulfate
- 30578-37-1 N
- 71926
- 64937 Y
- 03NR868ICX
- D01304 Y
- CHEBI:31201
- ChEMBL2106667 N
- DTXSID00184657
- Interactive image
- COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2.COS(=O)(=O)[O-]
InChI
- InChI=1S/C11H11N3O.CH4O4S/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10;1-5-6(2,3)4/h2-8,12H,1H3;1H3,(H,2,3,4) Y
- Key:ZEASXVYVFFXULL-UHFFFAOYSA-N Y
Amezinium metilsulfate (INN, trade name Regulton) is a sympathomimetic drug used for the treatment of low blood pressure. It has multiple mechanisms, including stimulation of alpha and beta-1 receptors and inhibition of noradrenaline and tyramine uptake.[1][2]
References
- ^ Araújo D, Caramona MM, Osswald W (June 1983). "On the mechanism of action of amezinium methylsulphate on the dog saphenous vein". European Journal of Pharmacology. 90 (2–3): 203–14. doi:10.1016/0014-2999(83)90238-8. PMID 6873182.
- ^ Lenke D, Gries J, Kretzschmar R (1981). "Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action". Arzneimittel-Forschung. 31 (9a): 1558–65. PMID 7197970.
- v
- t
- e
Cardiac stimulants excluding cardiac glycosides (C01C)
dopaminergic agents
Adrenergic agonists |
| ||||||
---|---|---|---|---|---|---|---|
Dopamine agonists | |||||||
Both | |||||||
Unknown/ungrouped |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e